(Hypertension. 1997;29:1020-1024.)
© 1997 American Heart Association, Inc.
Articles |
From the Department of Biological Sciences, Lehman College, Bronx, NY (M.S.M.), and Departments of Psychology and Pharmacology and the Cardiovascular Center, University of Iowa (Iowa City).
Correspondence to Martin S. Muntzel, PhD, Lehman College (CUNY), Department of Biological Sciences, 250 Bedford Park Blvd W, Bronx, NY 10468-1589. E-mail msmlc{at}cunyvm.cuny.edu
| Abstract |
|---|
|
|
|---|
Key Words: blood pressure glucose clamp technique heart rate insulin sympathetic nervous system
| Introduction |
|---|
|
|
|---|
AV3V lesions may eliminate sympathetic responses to insulin by destroying cell bodies in the ablated area or by interrupting fibers of passage removed from the targeted region. Cell body regions within the lesion include the periventricular nuclei at the preoptic anteroventral hypothalamic level, the OVLT, the ventral portion of the median preoptic nucleus, and the medial edge of the preoptic nuclei.7 The lesion also interrupts a ventrally directed system of efferents originating from the SFO that contact neurons in the median preoptic nucleus and OVLT as well as cell groups in the suprachiasmatic and supraoptic nuclei.8
One way to determine which element of the AV3V is critical for sympathetic responses to insulin is to fractionate the lesion into its component neural systems. For example, if the OVLT were the critical component, it would be expected that selective lesions of the OVLT would be equally effective in abolishing sympathetic responses to hyperinsulinemia. For the present studies, we tested the hypothesis that AV3V lesions abolish sympathoexcitation to insulin by disrupting fibers of passage that arise from the SFO. We focused on the SFO for the following reasons: First, the SFO sends an important set of efferent fibers through the AV3V8 ; second, the SFO is a well-known chemoreceptive circumventricular organ that lacks a blood-brain barrier7 ; third, the SFO contains high concentrations of insulin-specific binding sites9 10 ; and finally, the SFO functions to monitor blood-borne peptide hormones and to transmit this information into the central nervous system, thereby aiding in the regulation of body fluid balance and arterial blood pressure.7 In agreement with a sensory role for the SFO, intravenous injection of angiotensin II stimulates activity in SFO neurons, resulting in vasopressin release and elevations in sympathetic neural outflow.11 12 13 In addition, intravenous endothelin administration increases activity in SFO neurons, and microinjection of endothelin into the SFO causes elevations in blood pressure.14 Taken together, these findings are consistent with the hypothesis that blood-borne signals, such as insulin, activate specific receptors in the SFO, which send efferent signals through the AV3V region that eventually produce increases in peripheral sympathetic neural activity. Accordingly, the purpose of this study was first to determine once more whether lesions of the AV3V would abolish increases in sympathetic activity to hyperinsulinemia, and second to determine whether lesions of the SFO would have the same effect.
| Methods |
|---|
|
|
|---|
SFO Lesions
For SFO lesions, rats were anesthetized with ketamine (Henry
Schein, 40 mg/kg IM) and secured in a stereotaxic instrument (Kopf 900,
David Kopf Instruments). The scalp was incised on the midline and the
skull leveled between bregma and lambda. A 3-mm trephine hole was made
at bregma. SFO lesions were made with two or three penetrations of a
0.25-mm insulated nichrome wire electrode and a range of stereotaxic
coordinates. The most anterior stereotaxic coordinate was -1.3 or
-1.6 mm from bregma in the anterior-posterior plane, with the
next penetration(s) being 0.3 mm posterior to the previous one.
The electrode was lowered to a point 4.9 to 5.3 mm from the top of
the exposed midsagittal sinus, with the next penetration(s) being
0.2 mm lower than the previous. The angle of descent was 6° from
the perpendicular at a point 0.5 to 0.7 mm lateral to the middle
of the sinus so that retraction of the sinus was avoided. Anodal
current was passed through the bare tip at 1 mA for 8 to 10 seconds per
penetration. Sham lesions were produced by lowering the electrode to a
point 1.0 mm above the coordinates used for SFO lesions, and no
current was passed.
AV3V Lesions
For AV3V lesions, rats were anesthetized with ketamine and
secured in a Kopf 900 stereotaxic instrument with the skull leveled
between bregma and lambda. A lesioning electrode (24-gauge nichrome
wire insulated except at the tip) was lowered on the midline 0.3
mm caudal to bregma to a depth 7.5 mm from dura. Anodal current (2
to 3 mA) was passed for 25 to 30 seconds (rectal cathode). In
sham-lesioned rats, the electrode was lowered to a point 0.5 mm
above the intended target tissue, and no current was passed.
Surgical Procedure for Nerve Recording
After 4 weeks of recovery, rats were prepared for nerve
recording during euglycemic infusion of insulin. Anesthesia was induced
with 40 mg/kg methohexital sodium IP (Brevital, Eli Lilly Co) and
sustained with chloralose (Sigma Chemical Co; 50 mg/kg IV initially,
followed by 25 mg/kg per hour IV infusion). The trachea was cannulated
and each rat allowed to breathe oxygen-enriched air spontaneously. Body
temperature was kept near 37.5°C with a temperature-controlled
surgical table. Arterial pressure was monitored with a pressure
transducer (Statham P23XL) and displayed continuously on a polygraph
(model 7E, Grass Instrument Co). Heart rate was recorded from a linear
cardiotachometer (Grass model 7P4). Multifiber recordings of lumbar SNA
were obtained as previously described.3 Briefly, a midline
abdominal incision was made, and a lumbar sympathetic nerve was placed
on a bipolar platinum electrode (Cooner Wire Co) and covered with
silicone gel (Sil-Gel 604, Wacker-Chemie). Nerve signals were amplified
20x103 to 100x103 and filtered at low- and
high-frequency cutoffs of 100 and 1000 Hz, respectively, with a
preamplifier (Grass model P511). The amplified and filtered neurograms
were routed to a nerve traffic analyzer (model 706C, University of Iowa
Bioengineering) which counted the action potentials that exceeded a
threshold voltage set just above the noise level. A counter time bin
was set at 1 second so that the impulse frequency for SNA was displayed
on the polygraph as the number of spikes collected each second (hertz)
as a time-frequency histogram. For each experiment, baseline SNA was
set between 40 and 80 Hz.
Hyperinsulinemia With Euglycemic Clamp
Regular insulin (Iletin, Eli Lilly Co; 0.25 U/mL) in 50%
rat plasma in isotonic saline was administered through the femoral vein
with an infusion pump (model 255, Sage Instruments) at rates of 4.3 and
8.5 µU/min to obtain doses of approximately 0.06 and 0.13 U/h,
respectively. Arterial BG levels were measured every 5 minutes before
and during insulin infusion with a portable glucometer (Glucometer II,
model 5625, Miles Laboratory) that had been calibrated against a
glucose analyzer (model 27, Yellow Springs Instrument Co). For
maintenance of baseline BG, or euglycemia, 50% glucose in sterile
water was infused at variable rates through the jugular vein with an
adjustable peristaltic pump (Rabbit Peristaltic Pump, Rainin Instrument
Co). Reported BG values were determined with the glucose analyzer, and
PI levels were measured by radioimmunoassay.15
Experimental Protocols
The goal of the protocol was to determine the effects of
hyperinsulinemia on lumbar SNA in rats with either SFO lesions (n=12)
or AV3V lesions (n=4) and in rats with either sham SFO lesions (n=5) or
sham AV3V lesions (n=5). In control experiments, the vehicle for
insulin was infused in rats with sham lesions to the SFO (n=5) and in
rats with sham lesions to the AV3V (n=5). Thus, these experiments
consisted of six groups: four receiving insulin and two receiving the
vehicle for insulin. In all rats, basal levels of MAP, HR, lumbar SNA,
BG, and PI were obtained during a 15-minute control period. These
parameters were then monitored during 60 minutes of 0.06 U insulin/h
followed by 60 minutes of 0.13 U insulin/h in the four insulin-infused
groups or by identical volume infusion of vehicle in the two
vehicle-infused groups. PI and BG were obtained at the end of the
120-minute infusion period.
Histology
At the end of recording, deeply anesthetized rats were perfused
transcardially with physiological saline followed by 10% formalin.
Brains were removed and stored in fixative. Frozen 40-µm sections
through the area of the lesion in each brain were obtained and stained
with cresyl violet. The extent of brain damage was determined by light
microscopic examination in a single-blind fashion.
Statistical Analysis
Data were analyzed with appropriate single or repeated measures
ANOVA and presented as mean±SE. Post hoc comparisons were made with
Fisher's least significant difference tests. Differences between
groups were considered significant at a value of P<.05.
| Results |
|---|
|
|
|---|
|
AV3V lesion placement was verified as previously described.16 17 Lesions shared a common area of damage to the periventricular tissue surrounding the optic recess. The lesion consistently destroyed the periventricular nucleus at the preoptic level, the median preoptic nucleus, and the OVLT. Some bilateral damage was usually present at the medial edge of the preoptic nuclei.
Baseline Values
Baseline values and responses to the infusion procedure were
equivalent in SFO sham-lesioned rats and AV3V sham-lesioned rats
receiving the vehicle for insulin; therefore, these two groups were
pooled into a single sham-vehicle group (n=10, Table
).
In a similar fashion, baseline values and responses to the protocol
were similar in SFO sham-lesioned rats and AV3V sham-lesioned rats
receiving insulin; therefore, these two groups were pooled into a
single sham-insulin group (n=10). The rats with SFO lesions receiving
insulin (SFO-insulin, n=12) and those with AV3V lesions receiving
insulin (AV3V-insulin, n=4) remained the same as described in
"Methods." Comparisons of baseline values across the
sham-vehicle, sham-insulin, SFO-insulin, and AV3V-insulin groups
revealed no differences in BG, MAP, or HR. However, the SFO-insulin
group had significantly greater PI levels compared with the
sham-insulin and AV3V-insulin groups.
|
Responses to Vehicle and Insulin
ANOVA of BG levels revealed a groupbyrepeated measures
interaction (P<.01), reflecting increasing BG levels during
the 8 µL/min infusion period in the sham-vehicle group
(P<.01), contrasting with no change in BG in the other
experimental groups (Table
). PI levels did not change in the
sham-vehicle group but increased in a stepwise fashion during the 4
µL/min (P<.01) and 8 µL/min (P<.01)
infusion periods in the sham-insulin, SFO-insulin, and AV3V-insulin
groups. The increase in PI did not differ among these three groups. The
glucose infusion rate necessary to maintain stable levels of glycemia
increased in a stepwise fashion in the sham-insulin, SFO-insulin, and
AV3V-insulin groups during the 4 µL/min (P<.01) and 8
µL/min (P<.01) infusion periods and did not differ among
the groups. Vehicle and insulin infusions did not alter MAP and HR.
Lumbar SNA did not change during vehicle infusions in rats with sham
lesions (sham-vehicle group, Fig 2
). In sham-lesioned
rats receiving insulin infusion (sham-insulin group), lumbar SNA rose
significantly during low-dose insulin (P<.01). During
high-dose insulin, lumbar SNA continued to rise and increased
significantly (P<.001) over levels attained during the low
dose. Contrasting with this increase in lumbar SNA, and in agreement
with previous findings,4 insulin infusion had no effect on
lumbar SNA in rats with AV3V lesions (AV3V-insulin group). In rats with
SFO lesions (SFO-insulin group), insulin elicited a rise in lumbar SNA
that was indistinguishable from the rise in lumbar SNA observed in rats
with sham lesions.
|
| Discussion |
|---|
|
|
|---|
Interruption of sympathoexcitation to insulin by AV3V ablation, if not related to the SFO, could be mediated by several other brain regions. A likely candidate is the OVLT, one of the nuclear groups located within the AV3V region. The OVLT, like the SFO, is a circumventricular organ lacking a blood-brain barrier that monitors blood concentrations of peptide hormones, such as insulin, and transmits this information into the central nervous system.7 In accord with a blood-monitoring role for the OVLT, this region contains receptors for angiotensin II,18 19 atrial natriuretic peptide,19 and relaxin, a member of the insulin family of polypeptide hormones.20 Furthermore, the OVLT contains high concentrations of insulin-specific binding sites in cytoarchitectonically discrete regions9 and sends efferent projections to regions directly controlling sympathetic neural outflow.7 21 22
Lesions of the AV3V region may eliminate increased sympathetic activity in response to hyperinsulinemia by interrupting insulin uptake in the cerebral ventricles. In support of such a possibility, intravenous insulin administration in rats causes increased plasma insulin levels that are matched by parallel increases in CSF insulin.23 Once in the CSF, insulin may bind to receptors located on tanycyte cells lining the surface of the third ventricle.10 It has been postulated that these "CSF contacting neurons" participate in the uptake of insulin from the CSF into neuronal sites behind the brain-CSF barrier.7 10 Baskin and colleagues24 provided direct experimental support for this hypothesis by injecting radiolabeled insulin into the lateral ventricles of rats and found the highest radioactivity from both autoradiographic and microdissection procedures in the periventricular regions lining the third cerebral ventricle. Important in this context is our recent demonstration that insulin infusion into the third cerebral ventricle increases lumbar sympathetic activity in normotensive rats.5 Because AV3V lesions destroy the preoptic periventricular tissues, interruption of sympathoexcitation in the present study may be due to destruction of insulin-transporting tanycytes and consequent elimination of insulin transport from the CSF into the brain.
As a final possibility, it should be recalled that the AV3V region is part of an extensive neural network richly interconnected with other hypothalamic nuclei that receive input from cardiovascular and pulmonary sensory systems.7 AV3V lesions may interrupt fibers of passage from these regions, many of which could be important in generating sympathetic increases to intravenously administered insulin.
In summary, the present study demonstrated that lesions of the AV3V region abolish increases in sympathetic activity to intravenous insulin infusion, whereas lesions of the SFO have no effect on insulin-induced sympathoexcitation. These data indicate that the SFO itself and fibers originating from the SFO are not essential in mediating elevations in lumbar SNA to euglycemic hyperinsulinemia. Thus, by eliminating the SFO, we have ruled out the likelihood that AV3V lesions abolish sympathetic increases to insulin simply by removing critical input from the SFO that is transmitted to or through the AV3V for the mobilization of sympathetic outflow.
| Selected Abbreviations and Acronyms |
|---|
|
| Acknowledgments |
|---|
Received June 19, 1996; first decision September 14, 1996; accepted October 29, 1996.
| References |
|---|
|
|
|---|
2. Berne C, Fagius J, Pollare T, Hjemdahl P. The sympathetic response to euglycaemic hyperinsulinemia: evidence from microelectrode nerve recordings in healthy subjects. Diabetologia. 1992;35:873-879. [Medline] [Order article via Infotrieve]
3.
Morgan DA, Balon TW, Ginsberg BH, Mark AL.
Nonuniform regional sympathetic nerve responses to hyperinsulinemia in
rats. Am J Physiol. 1993;264:R423-R427.
4.
Muntzel M, Beltz T, Mark AL, Johnson AK.
Anteroventral third ventricle lesions abolish sympathetic neural
responses to hyperinsulinemia. Hypertension. 1994;23:1059-1062.
5.
Muntzel MS, Morgan DA, Mark AL, Johnson AK.
Intracerebroventricular administration of insulin produces nonuniform
increases in sympathetic nerve activity. Am J
Physiol. 1994;267:R1350-R1355.
6.
Anderson EA, Mark AL. The vasodilator action of
insulin: implications for the insulin hypothesis of
hypertension. Hypertension. 1993;21:136-141.
7. Johnson AK, Gross PM. Sensory circumventricular organs and brain homeostatic pathways. FASEB J. 1993;7:678-686. [Abstract]
8. Lind RW, Johnson AK. Subfornical organ-median preoptic connections and drinking and pressor responses to angiotensin II. J Neurosci. 1982;2:1043-1051. [Abstract]
9.
van Houten M, Posner BI, Kopriwa BM, Brawer JR.
Insulin-binding sites in the rat brain: in vivo
localization to the circumventricular organs by quantitative
radioautography. Endocrinology. 1979;105:666-673.
10. Unger JW, Livingston JN, Moss AM. Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol. 1991;36:343-362. [Medline] [Order article via Infotrieve]
11. McKinley MJ, McAllen RM, Mendelsohn FAO, Allen AM, Chai SY, Oldfield BJ. Circumventricular organs: neuroendocrine interfaces between the brain and the hemal milieu. Front Neuroendocrinol. 1990;11:91-127.
12. Kadekaro M, Gross PM, Sokoloff L, Holcomb HH, Saavedra JM. Elevated glucose utilization in subfornical organ and pituitary neural lobe of the Brattleboro rat. Brain Res. 1983;275:189-193. [Medline] [Order article via Infotrieve]
13. Simpson JB. The circumventricular organs and the central actions of angiotensin. Neuroendocrinology. 1981;32:248-256. [Medline] [Order article via Infotrieve]
14. Wall KM, Nasr M, Ferguson AV. Actions of endothelin at the subfornical organ. Brain Res. 1992;570:180-187. [Medline] [Order article via Infotrieve]
15. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest. 1960;39:1157-1175.
16.
Sanders BJ, Knardahl S, Johnson AK. Lesions of
the anteroventral third ventricle and development of stress-induced
hypertension in the borderline hypertensive rat.
Hypertension. 1989;13:817-821.
17. Buggy J, Johnson AK. Pre-optic-hypothalamic periventricular lesions: thirst deficits and hypernatremia. Am J Physiol. 1977;233:R44-R52.
18. Van Houten M, Schiffrin EL, Mann JFE, Posner BI, Boucher R. Radioautographic localization of specific binding sites for blood-borne angiotensin II in the rat brain. Brain Res. 1980;186:480-485. [Medline] [Order article via Infotrieve]
19. Mendelsohn FA, Allen AM, Chai SY, Sexton PM, Figdor R. Overlapping distributions of receptors for atrial natriuretic peptide and angiotensin II visualized by in vitro autoradiography: morphological basis of physiological antagonism. Can J Physiol Pharmacol. 1987;65:1517-1521. [Medline] [Order article via Infotrieve]
20.
Osheroff PI, Phillips HS. Autoradiographic
localization of relaxin binding sites in rat brain. Proc
Natl Acad Sci U S A. 1991;88:6413-6417.
21. Brody MJ, Johnson AK. Role of the anteroventral third ventricle region in fluid and electrolyte balance, arterial pressure regulation, and hypertension. In: Martini L, Ganong WF, eds. Frontiers in Neuroendocrinology. New York, NY: Raven Press Publishers; 1980;6:249-292.
22. Fink GD, Buggy J, Haywood JR, Johnson AK, Brody MJ. Hemodynamic effects of electrical stimulation of forebrain angiotensin and osmosensitive sites. Am J Physiol. 1978;235:H445-H451.
23.
Stein LJ, Dorsa DM, Baskin DG, Figlewicz DP, Porte D
Jr, Woods S. Reduced effect of experimental peripheral
hyperinsulinemia to elevate cerebrospinal fluid insulin concentrations
of obese Zucker rats. Endocrinology. 1987;121:1611-1615.
24.
Baskin DG, Woods SC, West DB, van Houten M, Posner BI,
Dorsa DM, Porte D Jr. Immunocytochemical detection of insulin in rat
hypothalamus and its possible uptake from cerebrospinal fluid.
Endocrinology. 1983;113:1818-1825.
This article has been cited by other articles:
![]() |
M. S. Muntzel Insulin-mediated sympathoexcitation in obesity and type 2 diabetes Nephrol. Dial. Transplant., October 1, 1999; 14(10): 2282 - 2285. [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1997 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |